Shimadzu Scientific Instruments (SSI), the American arm of Japan-based Shimadzu, has opened a new research and development (R&D) centre in the US.

The centre is spread across three locations – a laboratory at SSI’s headquarters in Columbia, Maryland, an East Coast lab near Boston, Massachusetts, and a West Coast lab near San Francisco, California.

The East Coast and West Coast labs will primarily investigate the needs of pharmaceutical companies and will jointly evaluate prototypes developed based on those needs.

Both Boston and San Francisco are biopharmaceutical hubs, making them good locations for Shimadzu’s operations.

The third laboratory, in Maryland, will be used to evaluate prototypes and undertake agile development in cooperation with the analytical and measuring instruments division of Shimadzu. The facility will also provide installation of prototypes and new products and conduct joint research with customers.

The new R&D operations will enable Shimadzu to understand customer needs better and accelerate product and technology development. They will expand on the capabilities of the company’s existing US innovation centre (established in 2015) and increase Shimadzu’s presence in the North American market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Shimadzu plans to use its SSI base to expand its business to pharmaceutical companies, increasing sales in North America from Y51bn ($374m) in fiscal 2022 to more than Y70bn ($457m) in fiscal 2025.

This is Shimadzu’s second such investment in recent times. In March, it opened a new regional hub in Dubai, UAE.

Headquartered in Kyoto, Shimadzu manufactures precision instruments, measuring instruments and medical equipment. Its American subsidiary was founded in 1975 and serves customers in multiple markets, including pharmaceutical, clinical, energy and forensics.